A refractory duodenal ulcer with a biliar

Yohei Horibe; Seiji AdAchi; Mitsuru Okuno; Tomohiko Ohno; Naoe Goto; Midori Iwama; Osamu Yamauchi; Koshiro Saito; Ichiro Yasuda; Masahito Shimizu

A refractory duodenal ulcer with a biliar

Yohei Horibe, Seiji AdAchi, Mitsuru Okuno, Tomohiko Ohno, Naoe Goto, Midori Iwama, Osamu Yamauchi, Koshiro Saito, Ichiro Yasuda, Masahito Shimizu

Hematology

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

A 65-year-oId woman with recurrent breast cancer was repeatedly treated with bevacizumab, an anti-VEGF antibody. In addition, she was also frequently prescribed a nonsteroidal anti-inflammatory drug for abdominal pain. Melena was revealed 2 months after the final treatment with bevacizumab, and an endoscopic study revealed a duodenal ulcer (DU) that was resistant to anti-ulcer therapy. A cholangiography identified a biliary-duodenal fistula with bile juice leaking from the ulcer base. Therefore, a biliary stent was placed into the common bile duct for 3 months until the DU healed. This is the first case of a refractory DU with a biliary-duodenal fistula in a patient treated with bevacizumab.

Original language	English
Pages (from-to)	1244-1250
Number of pages	7
Journal	Journal of Japanese Society of Gastroenterology
Volume	113
Issue number	7
Publication status	Published - 07-2016

All Science Journal Classification (ASJC) codes

Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{c5f64ae321f94e6c899b935beb240cc2,

title = "A refractory duodenal ulcer with a biliar",

abstract = "A 65-year-oId woman with recurrent breast cancer was repeatedly treated with bevacizumab, an anti-VEGF antibody. In addition, she was also frequently prescribed a nonsteroidal anti-inflammatory drug for abdominal pain. Melena was revealed 2 months after the final treatment with bevacizumab, and an endoscopic study revealed a duodenal ulcer (DU) that was resistant to anti-ulcer therapy. A cholangiography identified a biliary-duodenal fistula with bile juice leaking from the ulcer base. Therefore, a biliary stent was placed into the common bile duct for 3 months until the DU healed. This is the first case of a refractory DU with a biliary-duodenal fistula in a patient treated with bevacizumab.",

author = "Yohei Horibe and Seiji AdAchi and Mitsuru Okuno and Tomohiko Ohno and Naoe Goto and Midori Iwama and Osamu Yamauchi and Koshiro Saito and Ichiro Yasuda and Masahito Shimizu",

year = "2016",

month = jul,

language = "English",

volume = "113",

pages = "1244--1250",

journal = "Journal of Japanese Society of Gastroenterology",

issn = "0446-6586",

publisher = "Japanese Society of Gastroenterology",

number = "7",

}

TY - JOUR

T1 - A refractory duodenal ulcer with a biliar

AU - Horibe, Yohei

AU - AdAchi, Seiji

AU - Okuno, Mitsuru

AU - Ohno, Tomohiko

AU - Goto, Naoe

AU - Iwama, Midori

AU - Yamauchi, Osamu

AU - Saito, Koshiro

AU - Yasuda, Ichiro

AU - Shimizu, Masahito

PY - 2016/7

Y1 - 2016/7

N2 - A 65-year-oId woman with recurrent breast cancer was repeatedly treated with bevacizumab, an anti-VEGF antibody. In addition, she was also frequently prescribed a nonsteroidal anti-inflammatory drug for abdominal pain. Melena was revealed 2 months after the final treatment with bevacizumab, and an endoscopic study revealed a duodenal ulcer (DU) that was resistant to anti-ulcer therapy. A cholangiography identified a biliary-duodenal fistula with bile juice leaking from the ulcer base. Therefore, a biliary stent was placed into the common bile duct for 3 months until the DU healed. This is the first case of a refractory DU with a biliary-duodenal fistula in a patient treated with bevacizumab.

AB - A 65-year-oId woman with recurrent breast cancer was repeatedly treated with bevacizumab, an anti-VEGF antibody. In addition, she was also frequently prescribed a nonsteroidal anti-inflammatory drug for abdominal pain. Melena was revealed 2 months after the final treatment with bevacizumab, and an endoscopic study revealed a duodenal ulcer (DU) that was resistant to anti-ulcer therapy. A cholangiography identified a biliary-duodenal fistula with bile juice leaking from the ulcer base. Therefore, a biliary stent was placed into the common bile duct for 3 months until the DU healed. This is the first case of a refractory DU with a biliary-duodenal fistula in a patient treated with bevacizumab.

UR - http://www.scopus.com/inward/record.url?scp=85011774880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011774880&partnerID=8YFLogxK

M3 - Article

C2 - 27383109

AN - SCOPUS:85011774880

SN - 0446-6586

VL - 113

SP - 1244

EP - 1250

JO - Journal of Japanese Society of Gastroenterology

JF - Journal of Japanese Society of Gastroenterology

IS - 7

ER -

A refractory duodenal ulcer with a biliar

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this